Table 1.
Demographic and clinical characteristics of study participantsa.
|
Group1 (n = 79) |
Group 2 (n = 123) |
P-value |
Group 3 (n = 24) |
||||
|---|---|---|---|---|---|---|---|
| % | % | Group 2 vs Group 1 |
% | ||||
| Age | 75.6 ± 14.0 | 75.4 ± 11.2 | 0.223 | 45.1 ± 14.1 | |||
| Male | 42 | 53.2 | 85 | 69.1 | 0.112 | 20 | 83.3 |
| Comorbidities | |||||||
| Hypertension | 30 | 38.0 | 60 | 48.8 | 0.554 | 0 | 0 |
| Cardiovascular diseases | 20 | 25.3 | 26 | 21.1 | 0.100 | 0 | 0 |
| Diabetes | 11 | 13.9 | 31 | 25.2 | 0.282 | 0 | 0 |
| Respiratory diseases | 8 | 10.1 | 6 | 4.9 | 0.255 | 0 | 0 |
| Cancer | 2 | 2.5 | 9 | 7.3 | 0.317 | 0 | 0 |
| Sepsis | 3 | 3.8 | 6 | 4.9 | 0.716 | 0 | 0 |
| Kidney diseases | 15 | 19.0 | 14 | 11.4 | 0.335 | 0 | 0 |
| Obesity | 5 | 6.3 | 14 | 11.4 | <0.001 | 0 | 0 |
| Treatments | |||||||
| CPAP | 17 | 21.5 | 60 | 48.8 | 0.307 | 0 | 0 |
| Intubation | 4 | 5.1 | 22 | 17.9 | <0.001 | 0 | 0 |
| Tracheostomy | 1 | 1.3 | 3 | 2.4 | <0.001 | 0 | 0 |
a
Group1: mild COVID-19; Group 2: severe COVID-19; Group 3: healthy subjects.